Infliximab products neutralize the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibit binding of TNFα with its receptors.

Indications:

NFLECTRA is indicated for: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy, and reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.

Route: intravenous

Dose:

The recommended dosage of INFLECTRA is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active CD.

Adverse Reactions:

An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion.

Contraindication:

The use of INFLECTRA at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure

Warnings and Precautions:

Patients treated with infliximab products are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.

Job Code:

Description:

See package insert for full prescribing information.